Geron Corp (GERN)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Geron Corp (GERN)
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Key Insights
Critical company metrics and information
Share Price
$3.93Market Cap
$2.38 BillionTotal Outstanding Shares
604.50 Million SharesTotal Employees
141Dividend
No dividendIPO Date
July 31, 1996SIC Description
Pharmaceutical PreparationsHomepage
https://www.geron.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $-215.61 Million |
Net Cash Flow, Continuing | $30.95 Million |
Net Cash Flow From Financing Activities, Continuing | $201.49 Million |
Net Cash Flow From Investing Activities, Continuing | $45.08 Million |
Net Cash Flow From Operating Activities, Continuing | $-215.61 Million |
Net Cash Flow From Investing Activities | $45.08 Million |
Net Cash Flow | $30.95 Million |
Net Cash Flow From Financing Activities | $201.49 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Basic Earnings Per Share | $0.32 |
Net Income/Loss Available To Common Stockholders, Basic | $-201.19 Million |
Income/Loss From Continuing Operations After Tax | $-201.19 Million |
Operating Income/Loss | $-207.97 Million |
Operating Expenses | $237.45 Million |
Income/Loss From Continuing Operations Before Tax | $-146.47 Million |
Costs And Expenses | $232.44 Million |
Net Income/Loss | $-201.19 Million |
Depreciation and Amortization | $518000.00 |
Net Income/Loss Attributable To Parent | $-201.19 Million |
Diluted Earnings Per Share | $0.32 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Benefits Costs and Expenses | $175.96 Million |
Basic Average Shares | $1.30 Billion |
Revenues | $29.48 Million |
Interest Expense, Operating | $12.12 Million |
Diluted Average Shares | $1.30 Billion |
Other Operating Expenses | $182.34 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $398.06 Million |
Fixed Assets | $1.59 Million |
Other Current Liabilities | $109.02 Million |
Equity | $292.28 Million |
Wages | $15.18 Million |
Liabilities And Equity | $444.95 Million |
Equity Attributable To Parent | $292.28 Million |
Current Liabilities | $137.93 Million |
Other Non-current Assets | $45.30 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Accounts Payable | $13.73 Million |
Other Current Assets | $377.77 Million |
Noncurrent Liabilities | $14.73 Million |
Liabilities | $152.67 Million |
Noncurrent Assets | $46.89 Million |
Assets | $444.95 Million |
Inventory | $20.28 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.